Advertisement

Anticoagulants

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu
Chapter

Abstract

The adverse cutaneous reactions associated with injectable anticoagulants such as unfractionated (standard) heparin, low molecular weight heparins (LMWHs) (enoxaparin, nadroparin [fraxiparin], certoparin, ardeparin, dalteparin, tinzaparin, bemiparin), direct thrombin inhibitors (argatroban), hirudins (desirudin, lepirudin, bivalirudin), synthetic pentasaccharides fondaparinux and idraparinux, heparinoids (danaparoid, pentosan polysulfate); and oral anticoagulants such as warfarin, acenocoumarol, fluindione, phenindione, direct thrombin inhibitor (dabigatran), and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) are reviewed in this section.

Keywords

Anticoagulants Heparin Low molecular weight heparin Enoxaparin Warfarin Bleeding/purpura Necrosis Eczema Angioedema/urticaria Bullous hemorrhagic dermatosis Vasculitis Alopecia Purple toe Drug rash with eosinophilia and systemic symptoms 

References

  1. 1.
    Maldonado Cid P, de Alonso Celada RM, Noguera Morel L, Feito-Rodríguez M, Gómez-Fernández C, Herranz Pinto P. Cutaneous adverse events associated with heparin. Clin Exp Dermatol. 2012;37:707–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Patel GK, Knight AG. Generalised cutaneous necrosis: a complication of low-molecular-weight heparin. Int Wound J. 2005;2:267–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Toll A, Gallardo F, Abella ME, Fontcuberta J, Barranco C, Pujol RM. Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states. Int J Dermatol. 2005;44:964–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Shelley WB, Sayen JJ. Heparin necrosis: an anticoagulant-induced cutaneous infarct. J Am Acad Dermatol. 1982;7:674–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Byrne JS, Abdul Razak AR, Patchett S, Murphy GM. Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase gene. Clin Exp Dermatol. 2004;29:35–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Valdivielso M, Longo I, Lecona M, Lázaro P. Cutaneous necrosis induced by acenocoumarol. J Eur Acad Dermatol Venereol. 2004;18:211–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Merklen-Djafri C, Mazurier I, Samama MM, Alhenc-Gelas M, Tortel MC, Cribier B, et al. Skin necrosis during long-term fluindione treatment revealing protein C deficiency. Ann Dermatol Venereol. 2012;139:199–203.Google Scholar
  9. 9.
    Beqqal K, Horellou MH, Philippe A, Alhene Gelas M, Flaujac C, Gorin I, et al. Skin necrosis due to fluindione treatment: a rare but serious complication. J Wound Care. 2014;23(2 Suppl):S16–9.Google Scholar
  10. 10.
    Warkentin TE, Whitlock RP, Teoh KH. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud’s phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Am J Hematol. 2004;75:56–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Klein L, Galvez A, Klein O, Chediak J. Warfarin-induced limb gangrene in the setting of lung adenocarcinoma. Am J Hematol. 2004;76:176–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis. 2002;46:29–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Klein GF, Kofler H, Wolf H, Fritsch PO. Eczema-like, erythematous, infiltrated plaques: a common side effect of subcutaneous heparin therapy. J Am Acad Dermatol. 1989;21:703–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Gupta S, Mishra P, Palaian S, Prabhu S, Bista D, Prabhu M. Probable cutaneous allergic response to subcutaneous heparin - a case report. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:98–101.Google Scholar
  15. 15.
    Méndez J, Sanchís ME, de la Fuente R, Stolle R, Vega JM, Martínez C, et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy. 1998;53:999–1003.Google Scholar
  16. 16.
    Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006;61:1432–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Enrique E, Alijotas J, Cistero A, san Miguel MM, Bartra J, Tresserra F. Patch-test positivity in cutaneous reactions to enoxaparin. Contact Dermatitis. 2000;42:43.PubMedGoogle Scholar
  18. 18.
    White JM, Munn SE, Seet JE, Adams N, Clement M. Eczema-like plaques secondary to enoxaparin. Contact Dermatitis. 2006;54:18–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Schiffner R, Glässl A, Landthaler M, Stolz W. Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids. Contact Dermatitis. 2000;42:49.PubMedGoogle Scholar
  20. 20.
    Koch P, Munssinger T, Rupp-John C, Uhl K. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. J Am Acad Dermatol. 2000;42:612–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg. 2001;27:47–52.PubMedGoogle Scholar
  22. 22.
    Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis. 2004;49:276–80.CrossRefGoogle Scholar
  23. 23.
    Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis. 2004;51:67–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Jappe U, Gollnick H. Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives. Hautarzt. 1999;50:406–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Zollner TM, Gall H, Völpel H, Kaufmann R. Type IV allergy to natural hirudin confirmed by in vitro stimulation with recombinant hirudin. Contact Dermatitis. 1996;35:59–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Koutsojannis CM, Kounis NG. Lepirudin anaphylaxis and Kounis syndrome. Circulation. 2004;109:315.CrossRefGoogle Scholar
  27. 27.
    Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003;108:2062–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis. 2004;51:149–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy. 2004;34:1916–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Tejedor Alonso MA, Lopez Revuelta K, Garcia Bueno MJ, Casas Losada ML, Rosado Ingelmo A, Gruss Vergara E, et al. Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient. Clin Nephrol. 2005;63:236–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Harr T, Scherer K, Tsakiris DA, Bircher AJ. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy. 2006;61:787–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Peña ZG, Suszko JW, Morrison LH. Hemorrhagic bullae in a 73-year-old man. Bullous hemorrhagic dermatosis related to enoxaparin use. JAMA Dermatol. 2013;149:871–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Dixit S, Fischer G, Lim A. Haemorrhagic purpura in an elderly man. BHD. Australas J Dermatol. 2013;54:228–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Villanueva CA, Nájera L, Espinosa P, Borbujo J. Bullous hemorrhagic dermatosis at distant sites: a report of 2 new cases due to enoxaparin injection and a review of the literature. Actas Dermosifiliogr. 2012;103:816–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Maldonado Cid P, de Moreno Alonso Celada R, Herranz Pinto P, Noguera Morel L, Feltes Ochoa R, Beato Merino MJ, et al. Bullous hemorrhagic dermatosis at sites distant from subcutaneous injections of heparin: a report of 5 cases. J Am Acad Dermatol. 2012;67:e220–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Perrinaud A, Jacobi D, Machet MC, Grodet C, Gruel Y, Machet L. Bullous hemorrhagic dermatosis occurring at sites distant from subcutaneous injections of heparin: three cases. J Am Acad Dermatol. 2006;54(2 Suppl):S5–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Beltraminelli H, Itin P, Cerroni L. Intraepidermal bullous haemorrhage during anticoagulation with low-molecular-weight heparin: two cases. Br J Dermatol. 2009;161:191–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Benatar J, Stewart RA. Cutaneous blood-filled vesicles on idraparinux. Lancet. 2008;372:1949.PubMedCrossRefGoogle Scholar
  39. 39.
    Dyson SW, Lin C, Jaworsky C. Enoxaparin sodium-induced bullous pemphigoid-like eruption: a report of 2 cases. J Am Acad Dermatol. 2004;51:141–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Greiner D, Schofer H. Allergic drug exanthema to heparin. Cutaneous reactions to high molecular and fractionated heparin. Hautarzt. 1994;45:569–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Figarella I, Barbaud A, Lecompte T, De Maistre E, Reichert-Penetrat S, Schmutz JL. Cutaneous delayed hypersensitivity reactions to heparins and heparinoids. Ann Dermatol Venereol. 2001;128:25–30.PubMedGoogle Scholar
  42. 42.
    To K, Reynolds C, Spinler SA. Rash associated with dabigatran etexilate. Pharmacotherapy. 2013;33:e23–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23:264–8.PubMedCrossRefGoogle Scholar
  44. 44.
    de Bats B, Rivard L, Bellemin B, Duflo F, Allaouchiche B, Chassard D. Leukocytoclastic vasculitis after injection of low-molecular-weight heparin (letter). Presse Med. 2000;29:1604.PubMedGoogle Scholar
  45. 45.
    Humeau-Commin A, Chatap G, Giraud K, Vincent JP. IgA vasculitis induced by low molecular weight heparin. Ann Dermatol Venereol. 2005;132:705–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Jiménez-Gonzalo FJ, Medina-Pérez M, Marín-Martín J. Acenocoumarol-induced leukocytoclastic vasculitis. Haematologica. 1999;84:462–3.PubMedGoogle Scholar
  47. 47.
    Aouam K, Gassab A, Khorchani H, Bel Hadj Ali H, Amri M, Boughattas NA, Zili JE. Acenocoumarol and vasculitis: a case report. Pharmacoepidemiol Drug Saf. 2007;16:113–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Hsu CY, Chen WS, Sung SH. Warfarin-induced leukocytoclastic vasculitis: a case report and review of literature. Intern Med. 2012;51:601–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Wang YY, Po HL. Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther. 2006;31:513–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Sarris E, Tsele E, Bagiatoudi G, Salpigidis K, Stavrianaki D, Kaklamanis L, Siakotos M. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis. 2003;41:E15.PubMedCrossRefGoogle Scholar
  51. 51.
    Apsner R, Horl WH, Sunder-Plassmann G. Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. Blood. 2001;97:2914–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Umlas J, Harken DE. Warfarin-induced alopecia. Cutis. 1988;42:63–4.PubMedGoogle Scholar
  53. 53.
    Nagao T, Ibayashi S, Fujii K, Sugimori H, Sadoshima S, Fujishima M. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet. 1995;346:1104–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Eich D, Scharffetter-Kochanek K, Weihrauch J, Krieg T, Hunzelmann N. Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. J Am Acad Dermatol. 2004;50:210–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Boccara O, Prost-Squarcioni C, Battistella M, Brousse N, Rongioletti F, Fraitag S. Calcinosis cutis: a rare reaction to subcutaneous injections of calcium-containing heparin in patients with renal failure. Am J Dermatopathol. 2010;32:52–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Campanelli A, Kaya G, Masouyé I, Borradori L. Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. Br J Dermatol. 2005;153:657–60.PubMedCrossRefGoogle Scholar
  57. 57.
    Al-Niaimi F, Clark C. A case of unilateral purple toes due to warfarin. Clin Exp Dermatol. 2009;34:527–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Dulíček P, Bártová J, Beránek M, Malý J, Pecka M. The purple toe syndrome in female with Factor V Leiden mutation successfully treated with enoxaparin. Clin Appl Thromb Hemost. 2013;19:100–2.PubMedCrossRefGoogle Scholar
  59. 59.
    Talmadge DB, Spyropoulos AC. Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome. Pharmacotherapy. 2003;23:674–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Piñero-Saavedra M, Castaño MP, Camarero MO, Milla SL. DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report. Blood Coagul Fibrinolysis. 2013;24:576–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Sparsa A, Bédane C, Benazahary H, De Vencay P, Gauthier ML, Le Brun V, et al. Drug hypersensitive syndrome caused by fluindione. Ann Dermatol Venereol. 2001;128:1014–8.PubMedGoogle Scholar
  62. 62.
    Frouin E, Roth B, Grange A, Grange F, Tortel MC, Guillaume JC. Hypersensitivity to fluindione (Previscan). Positive skin patch tests. Ann Dermatol Venereol. 2005;132:1000–2.PubMedCrossRefGoogle Scholar
  63. 63.
    Ronceray S, Dinulescu M, Le Gall F, Polard E, Dupuy A, Adamski H. Enoxaparin-induced DRESS syndrome. Case Rep Dermatol. 2012;4:233–7.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Katoh S, Terashima S, Nakahara Y, Yamada H, Tatsukawa H, Ida K, Nakagawa M. Hypersensitivity to heparin; a case report. Nihon Jinzo Gakkai Shi. 1993;35:411–4.PubMedGoogle Scholar
  65. 65.
    Mohamed SD. Sensitivity reaction to phenindione with urticaria, hepatitis, and pancytopenia. Br Med J. 1965;2:1475–6.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Naisbitt DJ, Farrell J, Chamberlain PJ, Hopkins JE, Berry NG, Pirmohamed M, Park BK. Characterization of the T-cell response in a patient with phenindione hypersensitivity. J Pharmacol Exp Ther. 2005;313:1058–65.PubMedCrossRefGoogle Scholar
  67. 67.
    Wright JS. Phenindione sensitivity with leukaemoid reaction and hepato-renal damage. Postgrad Med J. 1970;46:452–5.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Garnett ES, Pegrum GD, McDonald SJ. A fatal case of phenindione sensitivity. Br Med J. 1962;2:1032–3.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Komericki P, Grims R, Kränke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol. 2007;57:718–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Chtioui M, Cousin-Testard F, Zimmermann U, Amar A, Saiag P, Mahé E. Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing. Ann Dermatol Venereol. 2008;135:295–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Thurot C, Reymond JL, Bourrain JL, Pinel N, Beani JC. Fluindione-induced acute exanthematous pustulosis with renal involvement. Ann Dermatol Venereol. 2003;130(12 Pt 1):1146–9.PubMedGoogle Scholar
  72. 72.
    Smith KJ, Rosario-Collazo J, Skelton H. Delayed cutaneous hypersensitivity reactions to hirudin. Arch Pathol Lab Med. 2001;125:1585–7.PubMedGoogle Scholar
  73. 73.
    Mohammed KN. Symmetric fixed eruption to heparin. Dermatology. 1995;190:91.PubMedCrossRefGoogle Scholar
  74. 74.
    Shaheen S, Akhtar S. Fixed drug eruption due to heparin injection. JPMI. 2008;22:340–1.Google Scholar
  75. 75.
    Tsoumpris A, Tzimas T, Gkabrelas K, Akritidis N. Iron complex, dabigatran and toxic epidermal necrolysis syndrome: a case-report. J Clin Pharm Ther. 2013;38:177–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Pfeiff B, Pullmann H. Baboon-artiges Arzneiexanthem auf heparin. Dtsch Dermatologe. 1991;39:559–60.Google Scholar
  77. 77.
    Silverton NH. Skin pigmentation by phenindione. Br Med J. 1966;1:675.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations